<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Networking on BEHIND-MS</title>
    <link>https://www.behind-ms.eu/en/tags/networking/</link>
    <description>Recent content in Networking on BEHIND-MS</description>
    <generator>Hugo</generator>
    <language>en</language>
    <lastBuildDate>Tue, 12 Mar 2024 00:00:00 +0000</lastBuildDate>
    <atom:link href="https://www.behind-ms.eu/en/tags/networking/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>BEATsep</title>
      <link>https://www.behind-ms.eu/en/networking/beatsep/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/networking/beatsep/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.beatsepsis.eu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;BEATsep&lt;/a&gt;&#xA; represents an interdisciplinary approach, bringing together research teams addressing specific aspects of long-lasting consequences of sepsis and PICS development and clinicians specializing in the care of sepsis patients and clinicians involved in treating and preventing long-lasting results and PICS. Given the anticipated large volumes of data, we will leverage artificial intelligence (AI) algorithms to integrate our complex clinical and research data and create a readily applicable predictive tool capable of identifying sepsis patients at the highest risk of reduced quality of life.&lt;/p&gt;</description>
    </item>
    <item>
      <title>COMMUTE</title>
      <link>https://www.behind-ms.eu/en/networking/commute/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/networking/commute/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.commute-project.eu/en/about.html&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;COMMUTE&lt;/a&gt;&#xA;&lt;/p&gt;&#xA;&lt;p&gt;COMMUTE aims to estimate the risk of neurodegenerative disorders comorbidities after COVID-19 infection and understand the comorbidity between COVID and neurodegenerative disorders at the mechanistic level. Therefore, they will apply both a hypotheses-free, data-driven approach building on available big data as well as a hypothesis-driven, knowledge-based approach that leveraging the substantial knowledge in the scientific community.&lt;/p&gt;</description>
    </item>
    <item>
      <title>EBV-MS</title>
      <link>https://www.behind-ms.eu/en/networking/ebv-ms/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/networking/ebv-ms/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.uib.no/en/ebvms&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;EBV-MS&lt;/a&gt;&#xA;&lt;/p&gt;&#xA;&lt;p&gt;Targeting the Epstein-Barr virus to treat and prevent MS (EBV-MS) is a ground-breaking Horizon Europe-funded research project with leading universities and hospitals in Europe and the USA.  We are aiming to unveil the role of the Epstein-Barr virus (EBV) in the onset and progression of the Multiple Sclerosis (MS) disease.&lt;/p&gt;&#xA;&lt;p&gt;The aim of the project, led by the University of Bergen, is to understand why only a few EBV infected people develop MS, and define the underlying mechanism of this process. The project will also investigate whether targeting the EBV infection with antiviral treatments can improve the disease course or stop disease progression.&lt;/p&gt;</description>
    </item>
    <item>
      <title>ENT1DEP</title>
      <link>https://www.behind-ms.eu/en/networking/ent1dep/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/networking/ent1dep/</guid>
      <description>&lt;h2 id=&#34;enterovirus-linked-type-1-diabetes-exposed--mechanisms-and-prevention&#34;&gt;Enterovirus-linked Type 1 Diabetes Exposed – mechanisms and Prevention&lt;/h2&gt;&#xA;&lt;p&gt;The main goal of &lt;a href=&#34;https://ent1dep.eu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;ENT1DEP&lt;/a&gt;&#xA; is to generate new knowledge about the causal links between infectious diseases (IDs) and non-communicable diseases (NCDs), and the host factors regulating the outcomes of infections. It will focus on one of the best-known ID-NCD associations, where the causality awaits confirmation, i.e. the association between enterovirus infections (particularly by Coxsackieviruses B – CVBs) and Type 1 Diabetes (T1D).&lt;/p&gt;</description>
    </item>
    <item>
      <title>Homi-Lung</title>
      <link>https://www.behind-ms.eu/en/networking/homi-lung/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/networking/homi-lung/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;http://www.homilung.com/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;Homi-lung&lt;/a&gt;&#xA; investigates the relationship between cardiovascular disease progression and the immune and microbiome changes after pneumonia, thus enabling early identification of at-risk patients, and developing new treatments.&lt;/p&gt;</description>
    </item>
    <item>
      <title>ID-DarkMatter-NCD</title>
      <link>https://www.behind-ms.eu/en/networking/dark-matter/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/networking/dark-matter/</guid>
      <description>&lt;p&gt;&lt;a href=&#34;https://www.darkmatter-project.eu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;ID-DarkMatter-NCD&lt;/a&gt;&#xA;  aims to unravel the complex interplay of infectious diseases, genetic, and environmental factors in triggering immune related non-communicable diseases by following a multi-disease and multi-omics approach.&lt;/p&gt;</description>
    </item>
    <item>
      <title>POINT</title>
      <link>https://www.behind-ms.eu/en/networking/point/</link>
      <pubDate>Tue, 12 Mar 2024 00:00:00 +0000</pubDate>
      <guid>https://www.behind-ms.eu/en/networking/point/</guid>
      <description>&lt;p&gt;The mission of &lt;a href=&#34;https://point-health.eu/&#34; target=&#34;_blank&#34; rel=&#34;noopener&#34;&gt;POINT&lt;/a&gt;&#xA; is to mitigate the long-term health risks associated with COVID-19. It will delve into the relationship between the post-acute phase of COVID-19 and the emergence of non-communicable diseases, with a focus on the pulmonary, cardiovascular, and renal systems. By harnessing advanced biomarkers and a virtual twin model for personalized care, it aims to bridge the gap between scientific discoveries and their practical application in clinical settings.&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
